Lupin gets USFDA tentative approval for apixaban suspension
In short
Lupin received tentative USFDA approval for Apixaban Oral Suspension 1.25 mg/mL. The source says it is an alternative way to give anticoagulation therapy to adults.
This could help Lupin expand its product line, but the reporting does not say when it may launch or whether final approval has been given.
What the reporting says
Lupin received USFDA tentative approval for Apixaban Oral Suspension 1.25 mg/mL, according to the available reporting. The publisher summary says the product is an alternative administration option for adult patients requiring anticoagulation therapy. The reporting does not state launch timing, commercial terms, or whether final approval has also been granted.
Why it matters
Lupin received tentative USFDA approval for Apixaban Oral Suspension 1.25 mg/mL, a formulation described in the publisher summary as an alternative administration option for adults needing anticoagulation therapy. The reporting does not say whether final approval has been granted, when the product may reach market, or what the commercial impact could be. The immediate relevance is to Lupin and its U.S. product pipeline.